Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2013 | 06-2013 | 03-2013 | 12-2012 | 09-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,987,000 | 1,021,000 | 544,000 | 5,963,000 | 4,909,539 |
| Depreciation Amortization | 1,293,000 | 857,000 | 421,000 | 2,782,000 | 2,194,430 |
| Accounts receivable | 22,000 | -91,000 | -10,000 | 36,000 | 689,292 |
| Other Working Capital | -220,000 | -323,000 | -142,000 | -1,859,000 | 223,822 |
| Other Operating Activity | -1,383,000 | -287,000 | -353,000 | 2,392,000 | -205,822 |
| Operating Cash Flow | $1,699,000 | $1,177,000 | $460,000 | $9,314,000 | $7,811,261 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -842,000 | -565,000 | -274,000 | -1,795,000 | -1,409,193 |
| Net Acquisitions | -566,000 | N/A | N/A | -706,000 | -681,624 |
| Purchase Of Investment | N/A | N/A | N/A | -11,998,000 | N/A |
| Sale Of Investment | -3,380,000 | -1,507,000 | -1,834,000 | 8,936,000 | -2,246,183 |
| Other Investing Activity | 19,000 | 0 | 0 | 3,000 | 1,998 |
| Investing Cash Flow | $-4,769,000 | $-2,072,000 | $-2,108,000 | $-5,560,000 | $-4,335,002 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 3,524,000 | 3,150,000 | 2,248,000 | 784,000 | 788,358 |
| Debt Issued | N/A | N/A | N/A | 14,700,000 | N/A |
| Debt Repayment | N/A | N/A | N/A | -11,071,000 | -54,000 |
| Common Stock Issued | 180,000 | 142,000 | 69,000 | 1,850,000 | 1,570,411 |
| Common Stock Repurchased | -1,566,000 | -1,215,000 | -925,000 | -2,364,000 | -1,723,348 |
| Dividend Paid | -664,000 | -444,000 | -224,000 | -3,183,000 | -2,370,937 |
| Other Financing Activity | -6,301,000 | -5,901,000 | -5,901,000 | -521,000 | -520,849 |
| Financing Cash Flow | $-4,827,000 | $-4,268,000 | $-4,733,000 | $195,000 | $-2,310,365 |
| Exchange Rate Effect | -23,000 | -67,000 | -48,000 | 40,000 | 18,234 |
| Beginning Cash Position | 10,802,000 | 10,802,000 | 10,802,000 | 6,813,000 | 6,812,820 |
| End Cash Position | 2,882,000 | 5,572,000 | 4,373,000 | 10,802,000 | 7,996,948 |
| Net Cash Flow | $-7,920,000 | $-5,230,000 | $-6,429,000 | $3,989,000 | $1,184,128 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,699,000 | 1,177,000 | 460,000 | 9,314,000 | 7,811,261 |
| Capital Expenditure | -842,000 | -565,000 | -274,000 | -1,795,000 | -1,409,193 |
| Free Cash Flow | 857,000 | 612,000 | 186,000 | 7,519,000 | 6,402,068 |